CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 25, 2015--
Pharmaceuticals, Inc. today announced the pricing of its initial
public offering of 5,000,000 shares of its common stock at a public
offering price of $12.00 per share, before the underwriting discount.
All of the shares in the offering are being sold by Catabasis. In
addition, Catabasis has granted the underwriters a 30-day option to
purchase up to 750,000 additional shares of common stock at the public
offering price, less the underwriting discount. Catabasis’ common stock
has been approved for listing on the NASDAQ Global Market and is
expected to begin trading under the ticker symbol “CATB” today.
The offering is expected to close on June 30, 2015, subject to customary
Citigroup Global Markets Inc. and Cowen and Company, LLC are acting as
joint book-running managers for the offering. Oppenheimer & Co. Inc. and
Wedbush PacGrow are acting as co-managers for the offering.
A registration statement relating to the securities being sold in this
offering has been filed with and declared effective by the Securities
and Exchange Commission. The offering is being made only by means of a
prospectus. When available, copies of the final prospectus relating to
this offering may be obtained from Citigroup Global Markets Inc., c/o
Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY
11717, telephone: 1-800-831-9146, or email: email@example.com
or from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155
Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department,
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or jurisdiction.
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of novel
therapeutics using its proprietary Safely Metabolized And Rationally
Targeted, or SMART, linker technology platform. Catabasis's SMART linker
technology platform is based on the concept of treating diseases by
simultaneously modulating multiple targets in one or more related
disease pathways. Catabasis engineers bi-functional product candidates
that are conjugates of two molecules, or bioactives, each with known
pharmacological activity, joined by one of its proprietary SMART
linkers. The SMART linker conjugates are designed for enhanced efficacy
and improved safety and tolerability. Catabasis’s focus is on treatments
for rare diseases. Catabasis is also developing other product candidates
for the treatment of serious lipid disorders.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150625005572/en/
Source: Catabasis Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971